×
About 4,875 results

ALLMedicine™ Soft Tissue Sarcoma Center

Research & Reviews  1,583 results

Impact of Dynamic Contrast Enhanced and Diffusion-Weighted MR Imaging on Detection of E...
https://doi.org/10.1002/jmri.28236
Journal of Magnetic Resonance Imaging : JMRI; Erber BM, Reidler P et. al.

May 19th, 2022 - Diagnosis of residual or recurrent tumor in soft-tissue sarcomas (STS) is a differential diagnostic challenge since post-therapeutic changes impede diagnosis. To evaluate the diagnostic accuracy of quantitative dynamic contrast enhanced (DCE)-MRI ...

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma incl...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092704
BMC Cancer; Kawai A, Narahara H et. al.

May 14th, 2022 - Soft tissue sarcomas (STSs) are a heterogeneous group of cancers with over 100 described subtypes. While these cancers are infrequent, the prognosis is quite poor, particularly for those with stage IV metastatic disease. Patients for whom curative...

Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem-ion): study ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097299
BMC Cancer; Brügemann D, Lehner B et. al.

May 14th, 2022 - The standard of care treatment for soft tissue sarcoma of the extremities is a wide resection in combination with pre- or postoperative radiotherapy with high local control rates, sparing patients the necessity of amputation without compromising o...

Primitive Myxoid Mesenchymal Tumor of Infancy With Fatal Hemorrhage In Utero: A Case Re...
https://doi.org/10.1097/MPH.0000000000002474 10.1136/bcr.09.2011.4851
Journal of Pediatric Hematology/oncology; Haga M, Motojima Y et. al.

May 11th, 2022 - Primitive myxoid mesenchymal tumor of infancy (PMMTI) is a rare soft tissue sarcoma in childhood. We present the case of a newborn male who experienced a severe hemorrhage in utero from the tumor on the scalp. He died at the age of 24 hours owing ...

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT03449901

May 11th, 2022 - The investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1) expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with a decreased overall survival. Using the extracellular arginine deple...

see more →

Guidelines  6 results

Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of ...
https://doi.org/10.1016/j.prro.2021.04.005
Practical Radiation Oncology; Salerno KE, Alektiar KM et. al.

Jul 31st, 2021 - This guideline provides evidence-based recommendations addressing the indications for radiation therapy (RT), sequencing of local therapies, and appropriate dose and planning techniques for management of primary, operable, localized, soft tissue s...

Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Ch...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019908
Pediatric Blood & Cancer; Rogers TN, Seitz G et. al.

Feb 2nd, 2021 - The treatment of paratesticular rhabdomyosarcoma (PT-RMS) has varied over time and by cooperative group. The International Soft Tissue Sarcoma Database Consortium (INSTRuCT) is a collaboration of the Children's Oncology Group (COG) Soft Tissue Sar...

Appendix 3: Soft tissue sarcoma: MCBS eUpdate published online 5 May 2017(www.esmo.org/...
https://doi.org/10.1093/annonc/mdx241
Annals of Oncology : Official Journal of the European Soc...

Sep 9th, 2017 - Appendix 3: Soft tissue sarcoma: MCBS eUpdate published online 5 May 2017(www.esmo.org/Guidelines/Sarcoma-and-GIST).|2017| ,|administration & dosage,adverse effects,administration & dosage,adverse effects,administration & dosage,adverse effects,st...

Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2016.0078
Journal of the National Comprehensive Cancer Network : JN... von Mehren M, Randall RL et. al.

Jun 11th, 2016 - Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The eval...

Soft tissue sarcoma, version 2.2014.
https://doi.org/10.6004/jnccn.2014.0053
Journal of the National Comprehensive Cancer Network : JN... von Mehren M, Randall RL et. al.

Apr 11th, 2014 - These NCCN Guidelines Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma (STS) specific to the role of radiation therapy in the management of patients with retroperitoneal/intra-abdominal STS. The guidelines ha...

see more →

Drugs  22 results see all →

Clinicaltrials.gov  137 results

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT03449901

May 11th, 2022 - The investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1) expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with a decreased overall survival. Using the extracellular arginine deple...

Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
https://clinicaltrials.gov/ct2/show/NCT05109494

May 9th, 2022 - Standard treatment for soft tissue sarcomas is a combination of radiation therapy and surgery. Radiation therapy is usually done prior to the surgical removal of the tumor. Most commonly, conventionally fractionated radiotherapy is used for soft t...

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
https://clinicaltrials.gov/ct2/show/NCT05106777

May 6th, 2022 - The study population is patients with advanced osteosarcoma and soft tissue sarcoma who have failed in standard chemotherapy treatment. Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle. Investigators will evaluate ...

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT02500797

May 3rd, 2022 - PRIMARY OBJECTIVE: I. To evaluate the confirmed response rate of single agent nivolumab and dual agent nivolumab plus ipilimumab in patients with locally advanced/unresectable or metastatic soft tissue sarcoma. SECONDARY OBJECTIVES: I. To evaluate...

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
https://clinicaltrials.gov/ct2/show/NCT00346164

Apr 28th, 2022 - PRIMARY OBJECTIVES: I. Define a risk-based treatment strategy comprising observation only, adjuvant radiotherapy, or adjuvant chemoradiotherapy or neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy in yo...

see more →

News  186 results

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-toripalimab-for-small-cell-lung-cancer

Apr 21st, 2022 - The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer (SCLC), according to an announcement from Coherus BioSciences, Inc. and Shanghai Junshi Bio...

Net Guides: Childhood Tumors
https://www.onclive.com/view/net-guides-childhood-tumors

Mar 15th, 2022 - //THE ONLINE ONCOLOGIST™ American Society of Pediatric Hematology/Oncology The American Society of Pediatric Hematology/Oncology (ASPHO) is a multidisciplinary organization that works to promote the care of children and adolescents with blo...

Dr. Tap on Developing Treatment Opportunities in Soft Tissue Sarcomas
https://www.onclive.com/view/dr-tap-on-developing-treatment-opportunities-in-soft-tissue-sarcomas

Feb 2nd, 2022 - William D. Tap, MD, medical oncologist, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses developing treatment opportunities in soft tissue sarcomas. Soft tissue sarcomas represent approximately 80 diffe...

Olaparib/Temozolomide Shows Encouraging Efficacy, Manageable Safety in Uterine Leiomyosarcoma
https://www.onclive.com/view/olaparib-temozolomide-shows-encouraging-efficacy-manageable-safety-in-uterine-leiomyosarcoma

Jan 5th, 2022 - In patients with advanced uterine leiomyosarcoma (uLMS) whose tumors harbor a BRCA-like phenotype, the combination of olaparib (Lynparza) with temozolomide (Temodar) could represent a new standard of care, according to Matthew A. Ingham, MD. Resu...

Ribociclib/Everolimus Elicits Responses in Dedifferentiated Liposarcoma
https://www.onclive.com/view/ribociclib-everolimus-elicits-responses-in-dedifferentiated-liposarcoma

Dec 4th, 2021 - The combination of ribociclib (Kisqali) and everolimus (Afinitor) elicits responses in patients with advanced dedifferentiated liposarcoma (DDLPS) and offers a tolerable safety profile, according to Margaret von Mehren, MD, who added that these re...

see more →

Patient Education  16 results see all →